SHM responds to the House Energy and Commerce Republicans' request for information regarding opioid and substance use disorder treatment. This letter focuses specifically on the need to deregulate

The Mainstreaming Addiction Treatment Act (S. 2074) is the companion bill to H.R. 2482. This bill will increase access to buprenorphine, a lifesaving addiction treatment, by eliminating the "X

SHM sent a support letter to Reps. Blumenauer and Mullin for their legislation, the Overdose Prevention and Patient Safety Act.

SHM urges Congress to take action to address the opioid crisis facing the United States.

SHM submitted comments regarding the pain management questions in the HCAHPS survey to Medicare in the Outpatient Prospective Payment System (OPPS) proposed rule.

Along with other organizations, SHM signs onto a letter to CMS supporting antibiotic stewardship requirements for long term care facilities (LTCFs) in order to participate in Medicare programs.

We write to you as leading participants in the prescription drug supply chain – i.e., manufacturers, distributors, payers, physicians, pharmacies, testing laboratories, treatment providers – as

SHM submits comments on the HCAHPS survey pain communication questions in the 2019 Outpatient Prospective Payment System Rule.

SHM submitted comments to the Ways and Means Committee and subcommittee on health regarding the opioid epidemic.

SHM responds to the Senate Finance Committee request for feedback on policies to address the opioid epidemic.